Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.70 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | NQO2 | P16083 | 1/20 | 0.70 |
| ▸ | SMC2 | O95347 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.58 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.58 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990156 | 1.00 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29552961 | 1.00 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29992517 | 0.93 | MAP2K1 (0.67) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL26158812 | 0.92 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL18931263 | 0.91 | MAP2K1 (0.72) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL22567830 | 0.91 | MAP2K1 (0.75) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL15647748 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL30136939 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29992962 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL1488195 | 0.90 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2SMC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306171-A2 | FORMULATION COMPRISING A MEK INHIBITOR | Array Biopharma, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| EP-3702351-B1 | FORMULATION COMPRISING A MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2023-11-22 | — | — | EP | claimed |
| EP-3340989-B1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | claimed |
| CN-109336824-B | Preparation of and formulations comprising MEK inhibitors | 诺华股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-11376239-B2 | Pharmaceutical combinations | ARRAY BIOPHARMA INC (US) | 2022-07-05 | — | — | US | claimed |
| CN-109890386-B | Pharmaceutical combination | 阵列生物制药公司 | 2022-05-24 | — | — | CN | claimed |
| EP-3702351-A1 | FORMULATION COMPRISING A MEK INHIBITOR | Array Biopharma, Inc. (US) | 2020-09-02 | — | — | EP | claimed |
| US-20200230108-A1 | PHARMACEUTICAL COMBINATIONS | ARRAY BIOPHARMA INC. | 2020-07-23 | — | — | US | claimed |
| US-10398683-B2 | Preparation of and formulation comprising a MEK inhibitor | ARRAY BIOPHARMA INC. (US) | 2019-09-03 | — | — | US | claimed |
| US-20190105303-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-04-11 | — | — | US | claimed |
| CN-1874768-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-06 | — | — | CN | claimed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | claimed |
| CN-1652776-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2005-08-10 | — | — | CN | claimed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | claimed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | claimed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | claimed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376239-B2 | Pharmaceutical combinations | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 18/4885ABCB11 100/4885 |
| US-10398683-B2 | Preparation of and formulation comprising a MEK inhibitor | MAP3K19, BRAF, MAP3K7 | MAP2K1 42/4885MAP2K2 36/4885ABCB11 2566/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAP2K1 106/4885MAP2K2 108/4885ABCB11 1897/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885ABCB11 1896/4885 |
| US-20200230108-A1 | PHARMACEUTICAL COMBINATIONS | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 18/4885ABCB11 100/4885 |
| US-20190105303-A1 | PHARMACEUTICAL COMBINATIONS | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 18/4885ABCB11 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.